pneumovax

ApprovedBiologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

pneumovax is one of 91 biologic programs targeting Pneumococcal Infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pneumococcal InfectionActive, not recruiting

Liver TransplantActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaActive, not recruiting

Ataxia-TelangiectasiaActive, not recruiting

Pneumococcal InfectionApproved

Active, not recruiting

Liver TransplantApproved

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 3

Active, not recruiting

AsthmaApproved

Active, not recruiting

Ataxia-TelangiectasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

pneumovax

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

1 2

Veramyst

GSK

Preclinical

46 3

Xolair

Roche

Preclinical

25 4

Celexa

AbbVie

Preclinical

1 5

Atrovent

Boehringer Ingelheim

Preclinical

5 6

Formoterol Fumarate

AstraZeneca

Preclinical

8 7

Aciphex

Akero Therapeutics

Preclinical

2 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Tylenol

KKenvue Brands

Preclinical

1 10

DUPIXENT

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaccination2 trials

Early Versus Delayed Pneumococcal Vaccination in HIV

Completed·CCIHR Canadian HIV Trials Network·Phase 1/2·NCT00137605·79 enrolled

Pneumococcal Vaccination of Crohn Patients

Completed·SStatens Serum Institut·Phase 4·NCT01947010·151 enrolled

Asthma1 trial

Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00836641·70 enrolled

Clinical Trial1 trial

Clinical Trial of PCV24 in Adults

Completed·SSinovac Life Sciences Co., Ltd.·Phase 1·NCT06474377·170 enrolled

Antibody1 trial

Antibody Production in Immune Disorders

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00023504·21 enrolled

Immune1 trial

Perturbing of HIV Reservoir With Immune Stimulation

Completed·UUniversity of California, San Diego·N/A·NCT02707692·54 enrolled

8 more indications

Liver Transplant1 trial

Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients

Completed·HHelsinki University Central Hospital·Phase 4·NCT01781871·182 enrolled

Pneumococcal Infection1 trial

Humoral Determinants of Immunity to Pneumococcal Infection

Completed·VVA Office of Research and Development·Phase 4·NCT00304382·114 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

Completed·UUniversity of Minnesota·Phase 3·NCT00457977·181 enrolled

Ataxia-telangiectasia1 trial

Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients

Unknown status·SSheba Medical Center··NCT01075438·20 enrolled

Immune Response1 trial

Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)

Completed·KKEMRI-Wellcome Trust Collaborative Research Program·Phase 1·NCT03460730·100 enrolled

Vaccine1 trial

Pneumococcal Vaccine in Untreated CLL Patients

Completed·KKarolinska University Hospital·Phase 3·NCT01892618·134 enrolled

SLE1 trial

BLYS and IFN in SLE

Completed·UUniversity of Alabama at Birmingham··NCT00611611·39 enrolled

Unspecified1 trial

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

Completed·EEmory University·N/A·NCT01307449·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for pneumovax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pneumovax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pneumovax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

pneumovax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vaccination2 trials

Asthma1 trial

Clinical Trial1 trial

Antibody1 trial

Immune1 trial

Liver Transplant1 trial

Pneumococcal Infection1 trial

Chronic Obstructive Pulmonary Disease1 trial

Ataxia-telangiectasia1 trial

Immune Response1 trial

Vaccine1 trial

SLE1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News